Interleukin 12 gene therapy of MHC-negative murine melanoma metastases

Cancer Research

Volumn 58, Issue 6, 1998, Pages 1225-1230

  Nanni, Patrizia ^a,e   Rossi, Ilaria ^a   De Giovanni, Carla ^a   Landuzzi, Lorena ^b   Nicoletti, Giordano ^b   Stoppacciaro, Antonella ^c   Parenza, Mareilla ^d   Colombo, Mario P ^d   Lollini, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e Istituto di Cancerologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; GENE THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MOLECULAR CLONING; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANIMALS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; GENE THERAPY; H-2 ANTIGENS; IMMUNOCOMPROMISED HOST; INTERLEUKIN-12; LUNG NEOPLASMS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; TRANSDUCTION, GENETIC;

EID: 0032520919     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Garrido, F., Ruiz-Cabello, F., Cabrera, T., Perez-Villar, J. J., Lopez-Botet, M., Duggan-Keen, M., and Stern, P. L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today, 18: 89-95, 1997.
2. Ferrone, S., and Marincola, F. M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today, 16: 487-494, 1995.
3. Trinchieri, G. Interleukin-12: a proinflammatory cytokine with immunomodulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol., 13: 251-276, 1995.
4. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
5. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol., 153: 1697-1706, 1994.
6. Mu , J., Zou, J-P., Yamamoto, N., Tustsui, T., Tai, X-G., Kobayashi, M., Herrmann, S., Fujiwara, H., and Hamaoka, T. Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res., 55: 4404-4408, 1995.
7. Tannenbaum, C. S., Wicker, N., Armstrong, D., Tubbs, R., Finke, J., Bukowski, R. M., and Hamilton, T. A. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol., 156: 693-699, 1996.
8. Martinotti, A., Stoppacciaro, A., Vagliani, M., Melani, C., Spreafico, F., Wysocka, M., Parmiani, G., Trinchieri, G., and Colombo, M. P. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol., 25: 137-146, 1995.
9. Tahara, H., Zitvogel, L., Storkus, W. J., Zeh, H. J., III, McKinney, T. G., Schreiber, R. D., Gubler, U., Robbins, P. D., and Lotze, M. T. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol., 154: 6466-6474, 1995.
10. Cavallo, F., Signorelli, P., Giovarelli, M., Musiani, P., Modesti, A., Brunda, M. J., Colombo, M. P., and Forni, G. Antitumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst., 89: 1049-1058, 1997.
11. Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C., and Stoppacciaro, A. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res., 56: 2531-2534, 1996.
12. b gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. Int. J. Cancer, 59: 269-274, 1994.
13. Stoppacciaro, A., Melani, C., Parenza, M., Mastracchio, A., Bassi, C., Baroni, C., Parmiani, G., and Colombo, M. P. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon-γ. J. Exp. Med., 178: 151-161, 1993.
14. Lomedico, P. T., Veli, G., Hellmann, C. P., Dukovich, M., Giri, J. G., Pan, Y. C. E., Collier, K., Semionon, R., Kuo, A. D., and Mizel, S. B. Cloning and expression of interleukin-1 cDNA in Escherichia coli. Nature (Lond.), 304: 458-462, 1984.
15. Beutler, B., Krochein, N., Milsark, I. W., Luedke, C., and Cerami, A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science (Washington DC), 232: 977-982, 1986.
16. Gray, P. W., and Goeddel, D. V. Cloning and expression of murine immune interferon cDNA. Proc. Natl. Acad. Sci. USA. 80: 5842-5846, 1983.
17. Sgadari, C., Angiolillo, A. L., Cherney, B. W., Pike, S. E., Farber, J. M., Koniaris, L. G., Vanguri, P., Burd, P. R., Sheikh, N., Gupta, G., Teruya-Feldstein, J., and Tosato, G. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA, 93: 13791-13796, 1996.
18. Colombo, M. P., Jaenisch, R., and Wettstein, P. J. Endogenous retroviruses lead to the expression of a histocompatibility antigen detected by skin graft rejection. Proc. Natl. Acad. Sci. USA, 84: 189-193, 1987.
19. Colombo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., and Parmiani, G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med., 173: 889-897, 1991.
20. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst., 87: 581-586, 1995.
21. Gately, M. K., Warrier, R. R., Honasoge, S., Carvajal, D. M., Faherty, D. A., Connaughton, S. E., Anderson, T. D., Sarmiento, U., Hubbard, B. R., and Murphy, M. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocytes activity and induces production of IFN-γ in vivo. Int. Immunol., 6: 157-167, 1994.
22. Sarmiento, U. M., Riley, J. H., Knaack, P. A., Lipman, J. M., Becker, J. M., Gately, M. K., Chizzonite, R., and Anderson, T. D. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab. Invest., 71: 862-873, 1994.
23. Tare, N. S., Bowen, S., Warrier, R. W., Carvajal, D. M., Benjamin, W. R., Riley, J. H., Anderson, T. D., and Gately, M. K. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J. Interferon Cytokine Res., 15: 377-383, 1995.
24. Cohen, J. IL-12 deaths: explanation and a puzzle. Science (Washington DC), 270: 908, 1995.
25. Meko, J. B., Yim, J. H., Tsung, K., and Norton, J. A. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res., 55: 4765-4770, 1995.
26. Irvine, K. R., Rao, J. B., Rosenberg, S. A., and Restifo, N. P. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol., 156: 238-245, 1996.
27. Bramson, J. L., Hitt, M., Addison, C. L., Muller, W. J., Gauldie, J., and Graham, F. L. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum. Gene Ther., 7: 1995-2002, 1996.
28. Tahara, H., Zeh, H. J., III, Storkus, W. J., Pappo, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P. D., and Lotze, M. T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res., 54: 182-189, 1994.
29. Lollini, P-L., De Giovanni, C., Nicoletti, G., Bontadini, A., Tazzari, P. L., Landuzzi, L., Scotlandi, K., and Nanni, P. Enhancement of experimental metastatic ability by tumor necrosis factor α alone or in combination with interferon-γ. Clin. Exp. Metastasis, 8: 215-224, 1990.
30. Angiolillo, A. L., Sgadari, C., Taub, D. D., Liao, F., Farber, J. M., Maheshwari, S., Kleinman, H., Reaman, G. H., and Tosato, G. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med., 182: 155-162, 1995.